ERBB2 and breast carcinoma: The phase III EMILIA study [3] evaluated the safety and efficacy of T-DM1 compared with lapatinib plus capecitabine for HER2-positive patients with locally advanced breast cancer and MBC previously treated with trastuzumab and a taxane agent.